DE69621617T2 - Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva - Google Patents

Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva

Info

Publication number
DE69621617T2
DE69621617T2 DE69621617T DE69621617T DE69621617T2 DE 69621617 T2 DE69621617 T2 DE 69621617T2 DE 69621617 T DE69621617 T DE 69621617T DE 69621617 T DE69621617 T DE 69621617T DE 69621617 T2 DE69621617 T2 DE 69621617T2
Authority
DE
Germany
Prior art keywords
substituted
convulsiva
pyridinamines
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69621617T
Other languages
English (en)
Other versions
DE69621617D1 (de
Inventor
P Huger
Sathapana Kongsamut
P Smith
Lei Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE69621617D1 publication Critical patent/DE69621617D1/de
Application granted granted Critical
Publication of DE69621617T2 publication Critical patent/DE69621617T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69621617T 1995-07-27 1996-07-08 Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva Expired - Lifetime DE69621617T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50807195A 1995-07-27 1995-07-27
PCT/US1996/011408 WO1997004777A1 (en) 1995-07-27 1996-07-08 Use off unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents

Publications (2)

Publication Number Publication Date
DE69621617D1 DE69621617D1 (de) 2002-07-11
DE69621617T2 true DE69621617T2 (de) 2003-01-02

Family

ID=24021262

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621617T Expired - Lifetime DE69621617T2 (de) 1995-07-27 1996-07-08 Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva

Country Status (20)

Country Link
EP (1) EP0840609B1 (de)
JP (1) JP4189029B2 (de)
KR (1) KR100445629B1 (de)
CN (1) CN1184969C (de)
AR (1) AR003471A1 (de)
AT (1) ATE218343T1 (de)
AU (1) AU696007B2 (de)
CA (1) CA2225156C (de)
DE (1) DE69621617T2 (de)
DK (1) DK0840609T3 (de)
ES (1) ES2174081T3 (de)
HK (1) HK1015687A1 (de)
IL (1) IL122845A0 (de)
MX (1) MX9800774A (de)
NO (1) NO315148B1 (de)
NZ (1) NZ312577A (de)
PT (1) PT840609E (de)
TW (1) TW464497B (de)
WO (1) WO1997004777A1 (de)
ZA (1) ZA966254B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
FR2897614B1 (fr) * 2006-02-20 2008-05-23 Urogene Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032599A (en) * 1986-11-12 1991-07-16 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-l-yl)pyridinamines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US5179099A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-dihydro-1-(pyridinylamino)-indoles
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

Also Published As

Publication number Publication date
CA2225156A1 (en) 1997-02-13
JPH11510159A (ja) 1999-09-07
DE69621617D1 (de) 2002-07-11
AU6454796A (en) 1997-02-26
NO315148B1 (no) 2003-07-21
AR003471A1 (es) 1998-08-05
ES2174081T3 (es) 2002-11-01
NO980334D0 (no) 1998-01-26
CA2225156C (en) 2003-06-10
ATE218343T1 (de) 2002-06-15
KR19990035973A (ko) 1999-05-25
DK0840609T3 (da) 2002-09-30
KR100445629B1 (ko) 2004-10-14
ZA966254B (en) 1997-02-11
EP0840609A1 (de) 1998-05-13
TW464497B (en) 2001-11-21
IL122845A0 (en) 1998-08-16
WO1997004777A1 (en) 1997-02-13
HK1015687A1 (en) 1999-10-22
CN1184969C (zh) 2005-01-19
NO980334L (no) 1998-03-26
JP4189029B2 (ja) 2008-12-03
AU696007B2 (en) 1998-08-27
EP0840609B1 (de) 2002-06-05
CN1191486A (zh) 1998-08-26
MX9800774A (es) 1998-04-30
PT840609E (pt) 2002-10-31
NZ312577A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
DE69615025D1 (de) Benzamid-derivate und deren verwendung als vasopressin-antagonisten
DE69431880T2 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE69629721D1 (de) Carnamoyloxy derivate von mutilin und deren verwendung als antibakterielles mittels
DE69636313D1 (de) Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE69634122D1 (de) Heterocyclische amidverbindungen und deren medizinische verwendung
DE69523182T2 (de) Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
DE69430662T2 (de) Zusammensetzungen von fluorkohlenwasserstoffen und kohlenwasserstoffen
ATE186447T1 (de) Zusammensetzung und verwendung
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE59708905D1 (de) Injektionsformulierungen von avermectinen und milbemycinen
DE69418203D1 (de) Zementiermittel und ihre verwendung
DE69414028T2 (de) Lasersystem und Verwendung des Lasersystems
DE69632936D1 (de) Verwendung von Pyrrolverbindungen als Antifouling-Wirkstoff
DE69431201D1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE69813560D1 (de) Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69827393D1 (de) Kosmetische verwendung von bis-resorcinol-triazinderivaten
DE69621617T2 (de) Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
DE69533742D1 (de) Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis
DE69616760D1 (de) Verwendung von 4-tert-butyl-1-cyclohexanol als antioxidant
DE69412083D1 (de) Phenylpyrrolderivate und ihre verwendung als antipsychotika
DE59308823D1 (de) Verwendung von Thioalkandionen als Aromastoffe
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
DE69711542T2 (de) Derivate von substituierten Benzoylharnstoffen und diese enthaltende Medikamente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US